ArticleBiomedicines2022

Safety of FOLFIRI + Durvalumab +/- Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59.

Camille Evrard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.